Media & Press releases
Media
MOLECULAR THERAPY
September, 2025
Perineural delivery of AAV2/9 in non-human primates is a safe and efficient route for gene therapy in Charcot-Marie-Tooth diseases
MEDVALEE MONTPELLIER
May 22, 2024
Boost Invest Medvallée le dispositif s’affine et trouve ses cibles
LA METHODE SCIENTIFIQUE
June 20, 2022
Système nerveux : de l’autre côté du périphérique
BIOMEDICINES
June 19, 2022
Traumatic and diabetic Schwann cell demyelination is triggered by a transient mitochondrial calcium release through voltage dependent anion channel 1
BIOTECH FINANCES
February 21, 2022
Nervosave défie la CMT1A
LA MARSEILLAISE
April 30, 2021
Maladies de Charcot-Marie-Tooth : un espoir de traitement
Nature Communications
April 21, 2021
AAV2/9-mediated silencing of PMP22 prevents the development of pathological features in a rat model of Charcot-Marie-Tooth disease 1 A
INSERM
April 21, 2021
La thérapie génique, un espoir contre les maladies de Charcot‑Marie‑Tooth
AFNP
La myéline du nerf périphérique
Press releases
October 21, 2021
Foundation of Nervosave Therapeutics!
September, 2022
Sarah Abbas, MD, joins Nervosave Therapeutics as Chief Medical Officer
February, 2023
Nervosave Therapeutics set up a lab at Sanofi BioPark in Montpellier, France
September, 2023
Sam Azoulay, MD, MBA, joins Nervosave Therapeutics as consulting CEO